PRECIGEN INC

Precigen reports a $53.1M Q2 2026 revenue surge, first-quarter profit, and strong growth of PAPZIMEOS for RRP, driving future precision‑medicine expansion.

Explore how Precigen, Inc. uses gene and cell therapies to tackle immuno‑oncology, autoimmune disorders and infections, driving biotech innovation and investor interest.

Precigen Inc. tops Q1 2026 expectations with $21.6M in PAPZIMEOS™ revenue, a 145% jump, and a clear path to cash‑flow break‑even, driving investor confidence.

Precigen’s biotech breakthroughs in gene and cell therapy face fierce market volatility, with a negative P/E and fluctuating stock—investors weigh science versus profitability.

Precigen’s breakthrough gene‑cell therapies target oncology, autoimmune disease and infections, driving its biotech rise and attracting investors with a $1.36B market cap.

Precigen Inc. reports Q3 2025 earnings: $0.5 M net sales, FDA‑approved PAPZIMEOS for RRP, and outlook for revenue growth despite losses.

Precigen Inc.’s stock surged 144% in August 2025 after the FDA approved its pioneering therapy for a rare lung disease, boosting investor confidence and positioning the biopharmaceutical company for further growth.

The Tumor-Infiltrating Lymphocyte (TIL) Therapy Market is gaining momentum, driven by expanding oncology applications and advancements in cell-based immunotherapy.

Precigen Inc. is a biopharmaceutical company pioneering gene and cell therapies to tackle complex health issues, revolutionizing the healthcare industry with innovative solutions.

Precigen, Inc. is a biopharmaceutical company pioneering the development of groundbreaking gene and cell therapies to address various health issues, including immuno-oncology, autoimmune disorders, and infections.